
Boston Scientific Stockholders Approve Charter Amendments, Officer Exculpation
Boston Scientific Corporation's stockholders approved significant amendments to the Company's Third Restated Certificate of Incorporation at the 2026 Annual Meeting. These amendments eliminate supermajority voting provisions and provide for the exculpation of certain officers, becoming effective upon filing the Fourth Restated Certificate of Incorporation. Additionally, all 10 director nominees were elected, executive compensation was approved on an advisory basis, and the appointment of Ernst & Young LLP as auditor was ratified. Stockholders also approved an amendment to the Employee Stock Purchase Plan to increase reserved shares, while proposals to allow stockholders owning 25% to call a special meeting were not approved.
Key Highlights
- Stockholders approved amendments to eliminate supermajority voting provisions in the Certificate of Incorporation.
- Stockholders approved amendments to provide for exculpation of certain officers as permitted by Delaware law.
- All 10 director nominees were elected to the Board for a one-year term.
- Stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers.
- Stockholders ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026.
- Stockholders approved an amendment to the Employee Stock Purchase Plan to increase shares reserved for issuance.
- Stockholders did not approve the amendment to permit 25% stockholders to call a special meeting.
- Stockholders did not approve the stockholder proposal to give shareholders the ability to call for a special meeting.
Price Impact
More from BSX